Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Shanghai HeartCare Medical Technology Corporation Limited
上海心瑋醫療科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 6609)

APPROVAL BY THE CSRC FOR THE REGISTRATION OF THE SUBSCRIPTION OF NEW DOMESTIC SHARES UNDER SPECIFIC MANDATE

Reference is made to the announcements of Shanghai HeartCare Medical Technology Corporation Limited (the "**Company**") dated December 12, 2025 and January 16, 2026 (the "**Announcements**") and the circular dated December 31, 2025 (the "**Circular**") in relation to, among other things, the proposed issue of Domestic Shares under the Specific Mandate. Unless otherwise defined, terms used in this announcement shall have the same meanings as those defined in the Announcements and the Circular.

The board of directors (the "**Board**") of the Company is pleased to announce that the Company received the "Approval for the Registration of the Issue of Shares by Shanghai HeartCare Medical Technology Corporation Limited to Specific Recipients" (Zheng Jian License [2026] No. 1153) issued by the China Securities Regulatory Commission (the "**CSRC**") dated May 14, 2026 (the "**Date of Approval of Registration**"). Accordingly, the CSRC has approved the issue of new Domestic Shares by the Company to the Subscriber under the Subscription. The details regarding the approval are as follows:

1. The CSRC approves the application made by the Company for the registration of the issue of shares to specific recipients.

2. The issue shall be implemented strictly in accordance with the filings submitted to the CSRC.

3. The approval shall be valid for 12 months from the Date of Approval of Registration by the CSRC.

4. From the Date of Approval of Registration by the CSRC until the end of the issue, if the Company encounters any major issues, it shall promptly report to the CSRC and deal with them in accordance with the relevant regulations.

The Board will handle the Subscription and the issuance of Subscription Shares in accordance with the approval, the requirements of the relevant laws and regulations, as well as the Specific Mandate granted by the extraordinary general meeting of the Company held on January 16, 2026, and will comply with the requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and/or the relevant laws and regulations in making further announcement(s) as and when appropriate. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Shanghai HeartCare Medical Technology Corporation Limited
WANG Guohui
Chairman of the Board

Shanghai, May 21, 2026

As at the date of this announcement, the executive Directors are Mr. Wang Guohui, Ms. Zhang Kun and Mr. Wei Jiawei; the non-executive Directors are Mr. Ding Kui, Mr. Chen Shaoxiong and Mr. Chen Gang; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.